Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.35 USD
-0.18 (-7.11%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.35 USD
-0.18 (-7.11%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Zacks News
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 1.15% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Taysha Gene Therapies, Inc. (TSHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Believe Taysha Gene Therapies, Inc. (TSHA) Could Rally 608%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 608.2% upside potential for Taysha Gene Therapies, Inc. (TSHA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Company News for Apr 13, 2021
by Zacks Equity Research
Companies in the news are: NUAN, TSHA, CADE, NVDA